Glioma stem cell organoids: preclinical model of glioblastoma heterogeneity to explore resistance mechanisms to conventional treatment schedules.

Glioma stem cell organoids: preclinical model of glioblastoma heterogeneity to explore resistance mechanisms to conventional treatment schedules. - Patient-derived glioma stem cell organoids.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON44469

Enrollment

Registered

2017-09-08

Start date

2018-04-10

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glioma Primary brain tumor

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • MRI imaging suggestive for glioblastoma • > 18 years of age

Exclusion criteria

Exclusion criteria: • Karnofsky index

Design outcomes

Primary

Measure	Time frame
Intra-and inter organoid genetic and epigenetic heterogeneity that is representative for GM	—

Countries

Netherlands

Outcome results